Архиви на јавното здравје

Том. 14 Бр. 1 (2022): Архиви на јавно здравје
Клинички истражувања

Метаболни нарушувања при примена на втора генерација на антипсихотици

OnlineFirst (English) pdf 71-83 (English)
  • Ненси Манушева,
  • Зоја Бабинкостова,
  • Славица Арсова ,
  • Кадри Хаџихамза,
  • Андромаши Наумовска,
  • Снежана Марковиќ
Ненси Манушева
Department of Psychiatry and Medical Psychology, Faculty of Medicine, University "St. Cyril and Methodius "Skopje, Republic of North Macedonia, PHI University Clinic for Psychiatry, Skopje, Republic of North Macedonia
Зоја Бабинкостова
Department of Psychiatry and Medical Psychology, Faculty of Medicine, University "St. Cyril and Methodius "Skopje, Republic of North Macedonia, PHI University Clinic for Psychiatry, Skopje, Republic of North Macedonia
Славица Арсова
Department of Psychiatry and Medical Psychology, Faculty of Medicine, University "St. Cyril and Methodius "Skopje, Republic of North Macedonia, PHI University Clinic for Psychiatry, Skopje, Republic of North Macedonia
Кадри Хаџихамза
Department of Psychiatry and Medical Psychology, Faculty of Medicine, University "St. Cyril and Methodius "Skopje, Republic of North Macedonia, PHI University Clinic for Psychiatry, Skopje, Republic of North Macedonia
Андромаши Наумовска
Department of Psychiatry and Medical Psychology, Faculty of Medicine, “Ss. Cyril and Methodius" Skopje, Republic North Macedonia
Снежана Марковиќ
PHI University Clinic for Endocrinology, Diabetes and Metabolic Disorders, Skopje, Republic of North Macedonia
ДОИ: https://doi.org/10.3889/aph.2022.6041

Објавено 2022-06-23

Клучни зборови

  • метаболен синдром,
  • втора генерација антипсихотици,
  • психијатриски растројства

Како да се цитира

1.
Манушева Н, Бабинкостова З, Арсова С, Хаџихамза К, Наумовска А, Марковиќ С. Метаболни нарушувања при примена на втора генерација на антипсихотици . Arch Pub Health [Internet]. 2022 Jun. 23 [cited 2024 Jul. 16];14(1). Available from: https://id-press.eu/aph/article/view/6041

Авторско право(c) 2021 Nensy Z. Manusheva, Zoja Babinkostova , Slavica Arsova , Kadri Hadjihamza , Andromahi Naumovska, Snezana Markovic

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Апстракт

Втората генерација на антипсихотици (second generation antipsychotics–SGA)  предизвикуваат несакани ефекти преку пораст на телесна тежина,дислипидемии (холестеролемија, хипертриглицеридемија) како и засегната хомеостаза на гликозата во смисол на хипергликемија, резистентност на инсулин и појава на диабетес мелитус тип 2. Цел на ова истражување е да се испитаат метаболните промени кај пациентите третирани со SGA. Mатеријали и методи: Ова беше проспективна студија на 50 пациенти третирани со SGA (olanzapine, clozapine, risperidone, quetiapine, aripiprazole) на ЈЗУ Универзитетска клиника за психијатрија кои ги исполнуваа соодветните МКБ-10 критериуми. Беа следени следните параметри: анамнеза и преглед, ТА и пулс, висина, тежина, индекс на телесна маса (bodymassindex-BMI), кратка скала за психијатриска проценка(BPRS), скала за глобален клинички впечаток (CGI), дозата на ординираниот SGA, како и: гликемија на гладно, липиден статус, HDL, LDL, гликолизиран хемоглобин (HgA1C). Параметрите беа одредувани на почеток и после три месечен третман. Резултати: Испитаниците во однос на критериумите на метаболен синдром беа: 64% со поголем обем на струк, 53,2% со пораст на систолен и/или дијастолен крвен притисок, 31,3% со BMI>30, а 39% со пораст на гликемија и намалени вредности на HDLкај 23,4%. Со исполнети три и повеќе критериуми беа 18% од испитаниците. Статистичката анализа на разликите во анализираните параметри покажа статистички сигнификантни разлики  за CGI-S скорот (p=0.00007) и задијастолниот притисок (p=0.038).Добиена е корелација на еквивалентните дози на SGA со BMI (r= -0,637). Дискусија: Истражувањето ја потврди присутноста на метаболни нарушувања кај пациентите третирани со SGA. Иако на самиот почеток на третманот не постои битна разлика во однос на присуството на метаболниот синдром во однос на општата популација, сепак утврдена е корелација со BMI. Заклучок: Ова истражување покажа дека пациентите кои се третирани со втора генерација на антипсихотици треба да бидат мониторирани во текот на нивниот третман во однос на параметрите кои го сочинуваат метаболниот синдром, особено BMI.

OnlineFirst (English) pdf 71-83 (English)

Downloads

Download data is not yet available.

Референци

  1. Uçok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry 2008;7(1):58-62. DOI: https://doi.org/10.1002/j.2051-5545.2008.tb00154.x
  2. Lui K, Randhawa G, Totten V, Smith AE, Raese J. Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical Record. Prim Care Companion CNS Disord 2016;18(1). DOI: https://doi.org/10.4088/PCC.15m01849
  3. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 22;353(12):1209-23. DOI: https://doi.org/10.1056/NEJMoa051688
  4. Sharif Z. Side effects as influencers of treatment outcome. J Clin Psychiatry 2008;69(Suppl 30):38-43.
  5. JahrVedal TS, Steen NE, Birkeland KI, Dieset I, Reponen EJ, Laskemoen JF, et al. Adipokine levels are associated with insulin resistance in antipsychotics users independently of BMI. Psychoneuroendocrinology 2019;103:87-95. DOI: https://doi.org/10.1016/j.psyneuen.2019.01.001
  6. HuhnМ, NikolakopoulouА, Schneider-ThomaЈ, Krause М, Samara М, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394: 939–951. DOI: https://doi.org/10.1016/S0140-6736(19)31135-3
  7. Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 2020;7: 64–77. DOI: https://doi.org/10.1016/S2215-0366(19)30416-X
  8. Shulman M, Miller A, Misher J, Tentler A. Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach. J Multidiscip Healthc2014;7:489-501. Published 2014 Oct 31. DOI: https://doi.org/10.2147/JMDH.S49817
  9. Rojo LE, Gaspar PA, Silva H, Risco L, Arena P, Cubillos-Robles K, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. Pharmacol Res 2015; 101:74-85. DOI: https://doi.org/10.1016/j.phrs.2015.07.022
  10. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006 May;23(5):469-80. DOI: https://doi.org/10.1111/j.1464-5491.2006.01858.x
  11. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of Metabolic Syndrome. Circulation 2004;109:433–438. DOI: https://doi.org/10.1161/01.CIR.0000111245.75752.C6
  12. Lee S, Ko Y, Kwak C, et al. Gender differences in metabolic syndrome components among the Korean 66-year-old population with metabolic syndrome. BMC Geriatr 2016;16:27. DOI: https://doi.org/10.1186/s12877-016-0202-9
  13. Wang HH, Lee DK, Liu M, Portincasa P, Wang DQ. Novel insights into the pathogenesis and management of the metabolic syndrome. PediatrGastroenterolHepatolNutr 2020;23(3):189-230. DOI: https://doi.org/10.5223/pghn.2020.23.3.189
  14. Manusheva N, Chabukovska E, Babinkostova Z, Markovikj S. Hyponatremia in olanzapine treated patient. Macedonian Journal of Anaesthesia 2021;5(2):78-83.
  15. Pouragha H, Amiri M, Saraei M, Pouryaghoub G, Mehrdad R. Body impedance analyzer and anthropometric indicators; predictors of metabolic syndrome. J Diabetes Metab Disord 2021;1-10. DOI: https://doi.org/10.1007/s40200-021-00836-w
  16. Beigh SH, Jain S. Prevalence of metabolic syndrome and gender differences. Bioinformation 2012;8(13):613-616. DOI: https://doi.org/10.6026/97320630008613
  17. Pucci G, Alcidi R, Tap L, Battista F, Mattace-Raso F, Schillaci G. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacol Res 2017;120:34-42. DOI: https://doi.org/10.1016/j.phrs.2017.03.008
  18. Jiang B, Zheng Y, Chen Y, Chen Yi, Li Q, Zhu C, al. Age and gender-specific distribution of metabolic syndrome components in East China: role of hypertriglyceridemia in the SPECT-China study. LipidsHealth Dis2018;17:92. DOI: https://doi.org/10.1186/s12944-018-0747-z
  19. Mauvais-Jarvis F. Epidemiology of gender differences in diabetes and obesity. AdvExp Med Biol 2017;1043:3-8. DOI: https://doi.org/10.1007/978-3-319-70178-3_1
  20. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009;2(5-6):231-237. DOI: https://doi.org/10.1242/dmm.001180
  21. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). EurPsychiatry 2009;24(6):412-24. DOI: https://doi.org/10.1016/j.eurpsy.2009.01.005
  22. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus Statement: Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65(2):267-272. DOI: https://doi.org/10.4088/JCP.v65n0219
  23. Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg JC, t al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 2009;43(6):620-6. DOI: https://doi.org/10.1016/j.jpsychires.2008.11.001
  24. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010;375(9710):181-3. DOI: https://doi.org/10.1016/S0140-6736(09)61794-3
  25. Robinson DG, Schooler NR, Correll CU, John M, Kurian BT, Marcy P, et al. Psychopharmacological treatment in the RAISE-ETP study: Outcomes of a manual and computer decision support system based intervention. Am J Psychiatry 2018;175(2):169-179. DOI: https://doi.org/10.1176/appi.ajp.2017.16080919
  26. Attux C, Quintana MI, Chaves AC. Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up. Braz J Psychiatry 2007;29(4):346-9. DOI: https://doi.org/10.1590/S1516-44462006005000061
  27. Attux C, Martini LC, Elkis H, et al. A 6-month randomized controlled trial to test the efficacy of a lifestyle intervention for weight gain management in schizophrenia. BMC Psychiatry 2013;13:60. DOI: https://doi.org/10.1186/1471-244X-13-60
  28. Zhang J, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: A systematic review and meta-analysis. Int J Neuropsychopharmacol2013;16(6):1205-1218. DOI: https://doi.org/10.1017/S1461145712001277
  29. Kraal AZ, Ward KM, Ellingrod VL. Sex differences in antipsychotic related metabolic functioning in Schizophrenia Spectrum Disorders. Psychopharmacol Bull 2017;47(2):8-21.
  30. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123(2-3):225-33. DOI: https://doi.org/10.1016/j.schres.2010.07.012
  31. Raben AT, Marshe VS, Chintoh A, Gorbovskaya I, Müller DJ, Hahn MK. The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: A Systematic Review and Implications for Treatment. Front Neurosci 2018; 11:741. DOI: https://doi.org/10.3389/fnins.2017.00741
  32. Leucht S, Samara M, Heres S, Davis JM. Dose Equivalents for Antipsychotic Drugs: The DDD Method. Schizophr Bull 2016;42(Suppl 1):S90-S94. DOI: https://doi.org/10.1093/schbul/sbv167
  33. https://psychopharmacopeia.com/antipsychotic_conversion.php
  34. https://cpnp.org/guideline/essentials/antipsychotic-dose-equivalents